Recent progress in urinary proteome analysis for prostate cancer diagnosis and management

References

• Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–1092.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.
   PubMed Web of Science ®Google Scholar
• Blute ML Jr., Abel EJ, Downs TM, et al. Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol. 2015;12(8):435–444.
   PubMed Web of Science ®Google Scholar
• Albright F, Teerlink C, Werner TL, et al. Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site. BMC Cancer. 2012;12:138.
   PubMed Web of Science ®Google Scholar
• Stewart SB, Freedland SJ. Influence of obesity on the incidence and treatment of genitourinary malignancies. Urol Oncol. 2011;29(5):476–486.
   PubMed Web of Science ®Google Scholar
• Agalliu I, Leanza SM, Smith L, et al. Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population. Prostate. 2010;70(15):1716–1727.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–2246.
   PubMed Web of Science ®Google Scholar
• Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer–the post PSA era. Anticancer Res. 2009;29(8):3289–3298.
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–1328.
   PubMed Web of Science ®Google Scholar
• Ganeswaran D, Sweeney C, Yousif F, et al. Population-based linkage of health records to detect urological complications and hospitalisation following transrectal ultrasound-guided biopsies in men suspected of prostate cancer. World J Urol. 2014;32(2):309–315.
   PubMed Web of Science ®Google Scholar
• Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2013;189(1 Suppl):S12–17. discussion S17–18.
   PubMed Web of Science ®Google Scholar
• Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004;17(3):292–306.
   PubMed Web of Science ®Google Scholar
• Bourke L, Boorjian SA, Briganti A, et al. Survivorship and improving quality of life in men with prostate cancer. Eur Urol. 2015;68(3):374–383.
   PubMed Web of Science ®Google Scholar
• Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368(5):436–445.
   PubMed Web of Science ®Google Scholar
• Good DM, Thongboonkerd V, Novak J, et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res. 2007;6(12):4549–4555.
   PubMed Web of Science ®Google Scholar
• Gallo V, Egger M, McCormack V, et al. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement. Eur J Clin Invest. 2012;42(1):1–16.
   PubMed Web of Science ®Google Scholar
• Tabb DL. Quality assessment for clinical proteomics. Clin Biochem. 2013;46(6):411–420.
   PubMed Web of Science ®Google Scholar
• Frantzi M, Bhat A, Latosinska A. Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med. 2014;3(1):7.
   PubMedGoogle Scholar
• Mischak H, Critselis E, Hanash S, et al. Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies. Am J Epidemiol. 2015;181(9):635–647.
   PubMed Web of Science ®Google Scholar
• Mischak H, Delles C, Vlahou A, et al. Proteomic biomarkers in kidney disease: issues in development and implementation. Nat Rev Nephrol. 2015;11(4):221–232.
   PubMed Web of Science ®Google Scholar
• Deborah P. Two-dimensional gel electrophoresis and mass spectrometry for biomarker discovery. Proteomics Clin Appl. 2009;3(2):155–172.
   PubMed Web of Science ®Google Scholar
• Chevalier F. Highlights on the capacities of “Gel-based” proteomics. Proteome Sci. 2010;8:23.
   PubMed Web of Science ®Google Scholar
• Iwadate Y. Clinical proteomics in cancer research-promises and limitations of current two-dimensional gel electrophoresis. Curr Med Chem. 2008;15(23):2393–2400.
   PubMed Web of Science ®Google Scholar
• Marcus K, Joppich C, May C, et al High-resolution 2DE. Methods Mol Biol. 2009;519:221–240.
   PubMedGoogle Scholar
• Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis. 1997;18(11):2071–2077.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fonslow BR, Shan B, et al. Protein analysis by shotgun/bottom-up proteomics. Chem Rev. 2013;113(4):2343–2394.
   PubMed Web of Science ®Google Scholar
• DeSouza LV, Siu KW. Mass spectrometry-based quantification. Clin Biochem. 2013;46(6):421–431.
   PubMed Web of Science ®Google Scholar
• Mischak H, Schanstra JP. CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin Appl. 2011;5(1–2):9–23.
   PubMed Web of Science ®Google Scholar
• Latosinska A, Frantzi M, Vlahou A, et al. Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: focus on bladder cancer. Proteomics Clin Appl. 2013;7(11–12):779–793.
   PubMed Web of Science ®Google Scholar
• Klein J, Papadopoulos T, Mischak H, et al. Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine. Electrophoresis. 2014;35(7):1060–1064.
   PubMed Web of Science ®Google Scholar
• Mischak H, Allmaier G, Apweiler R, et al Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010;2(46):46ps42.
   PubMed Web of Science ®Google Scholar
• Mischak H, Vlahou A, Ioannidis JP. Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem. 2013;46(6):432–443.
   PubMed Web of Science ®Google Scholar
• Mischak H, Ioannidis JP, Argiles A, et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest. 2012;42(9):1027–1036.
   PubMed Web of Science ®Google Scholar
• Brennan DJ, O’Connor DP, Rexhepaj E, et al. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer. 2010;10(9):605–617.
   PubMed Web of Science ®Google Scholar
• Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009;27(7):633–641.
   PubMed Web of Science ®Google Scholar
• Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat Methods. 2013;10(1):28–34.
   PubMed Web of Science ®Google Scholar
• Kiprijanovska S, Stavridis S, Stankov O, et al Mapping and identification of the urine proteome of prostate cancer patients by 2D PAGE/MS. Int J Proteomics. 2014;2014:594761–594761.
   PubMedGoogle Scholar
• Davalieva K, Kiprijanovska S, Komina S, et al. Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer. Proteome Sci. 2015;13(1):2.
   PubMed Web of Science ®Google Scholar
• Geisler C, Gaisa NT, Pfister D, et al Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. BioMed Res Int. 2015;2015:454256–454256.
   PubMed Web of Science ®Google Scholar
• Jayapalan JJ, Ng KL, Shuib AS, et al. Urine of patients with early prostate cancer contains lower levels of light chain fragments of inter-alpha-trypsin inhibitor and saposin B but increased expression of an inter-alpha-trypsin inhibitor heavy chain 4 fragment. Electrophoresis. 2013;34(11):1663–1669.
   PubMed Web of Science ®Google Scholar
• Haj-Ahmad TA, Abdalla MAK, Haj-Ahmad Y. Potential urinary protein biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer. 2014;5(2):103–114.
   PubMed Web of Science ®Google Scholar
• Jedinak A, Curatolo A, Zurakowski D, et al. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. BMC Cancer. 2015;15:259.
   PubMed Web of Science ®Google Scholar
• Principe S, Kim Y, Fontana S, et al. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res. 2012;11(4):2386–2396.
   PubMed Web of Science ®Google Scholar
• Kim Y, Ignatchenko V, Yao CQ, et al. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics. 2012;11(12):1870–1884.
   PubMed Web of Science ®Google Scholar
• Li C, Zang T, Wrobel K, et al. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer. Anal Bioanal Chem. 2015;407(12):3393–3404.
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Schiffer E, Bauer HW, et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl. 2008;2(4):556–570.
   PubMed Web of Science ®Google Scholar
• Oberpenning F, Von Knobloch R, Sprute W, et al. DiaPat urine test for prostate cancer. Predictive value for results of transrectal ultrasound-guided prostate biopsies. Urologe. 2008;47(6):735–739.
   PubMed Web of Science ®Google Scholar
• Schiffer E, Bick C, Grizelj B, et al. Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany. Int J Urol. 2012;19(2):118–125.
   PubMed Web of Science ®Google Scholar
• M’Koma AE, Blum DL, Norris JL, et al. Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine. Biochem Biophys Res Commun. 2007;353(3):829–834.
   PubMed Web of Science ®Google Scholar
• True LD, Zhang H, Ye M, et al. CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol. 2010;23(10):1346–1356.
   PubMed Web of Science ®Google Scholar
• Bilgin Dogru E, Dizdar Y, Aksit E, et al. EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study. Tumour Biol. 2014;35(11):11647–11653.
   PubMed Web of Science ®Google Scholar
• Dudderidge TJ, Kelly JD, Wollenschlaeger A, et al. Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments. Br J Cancer. 2010;103(5):701–707.
   PubMed Web of Science ®Google Scholar
• Fujita K, Ewing CM, Chan DYS, et al. Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer. 2009;124(3):664–669.
   PubMed Web of Science ®Google Scholar
• Fujita K, Ewing CM, Isaacs WB, et al. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer. 2011;129(2):424–432.
   PubMed Web of Science ®Google Scholar
• Kollermann J, Schlomm T, Bang H, et al. Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol. 2008;54(6):1314–1323.
   PubMed Web of Science ®Google Scholar
• Katafigiotis I, Tyritzis SI, Stravodimos KG, et al. Zinc alpha 2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. BJU Int. 2012;110(11B):E688–E693.
   PubMed Web of Science ®Google Scholar
• Bose SK, Bullard RS, Donald CD. Oncogenic role of engrailed-2 (en-2) in prostate cancer cell growth and survival. Transl Oncogenomics. 2008;3:37–43.
   PubMedGoogle Scholar
• Morgan R, Boxall A, Bhatt A, et al. Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res. 2011;17(5):1090–1098.
   PubMed Web of Science ®Google Scholar
• Marszall MP, Sroka W, Adamowski M, et al. Engrailed-2 protein as a potential urinary prostate cancer biomarker: a comparison study before and after digital rectal examination. Eur J Cancer Prev. 2015;24(1):51–56.
   PubMed Web of Science ®Google Scholar
• Pandha H, Sorensen KD, Orntoft TF, et al. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int. 2012;110(6B):E287–E292.
   PubMed Web of Science ®Google Scholar
• Nakayama K, Inoue T, Sekiya S, et al. The C-terminal fragment of prostate-specific antigen, a 2331 Da Peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer. PLoS One. 2014;9(9):e107234.
   Web of Science ®Google Scholar
• Prager AJ, Peng CR, Lita E, et al. Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. Biomark Med. 2013;7(6):831–841.
   PubMed Web of Science ®Google Scholar
• Russo AL, Jedlicka K, Wernick M, et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res. 2009;15(13):4292–4298.
   PubMed Web of Science ®Google Scholar
• Varambally S, Laxman B, Mehra R, et al. Golgi Protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia. 2008;10(11):1285–U1104.
   PubMed Web of Science ®Google Scholar
• Wayner EA, Quek S-I, Ahmad R, et al. Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine. Prostate. 2012;72(9):1023–1034.
   PubMed Web of Science ®Google Scholar
• Whitaker HC, Kote-Jarai Z, Ross-Adams H, et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One. 2010;5(10):e13363.
   Web of Science ®Google Scholar
• Leyten GHJM, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014;65(3):534–542.
   PubMed Web of Science ®Google Scholar
• He J, Schepmoes AA, Shi T, et al. Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. J Transl Med. 2015;13:54.
   Web of Science ®Google Scholar
• Mueller H, Haug U, Rothenbacher D, et al. Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer. J Urol. 2008;180(4):1309–1312.
   PubMed Web of Science ®Google Scholar
• Sardana G, Diamandis EP. The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer. Clin Biochem. 2009;42(13–14):1483–1486.
   PubMed Web of Science ®Google Scholar
• Chen M, Wang K, Zhang L, et al. The discovery of putative urine markers for the specific detection of prostate tumor by integrative mining of public genomic profiles. PLoS One. 2011;6(12):e28552.
   Web of Science ®Google Scholar
• Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst. 2008;100(20):1432–1438.
   PubMed Web of Science ®Google Scholar
• Altman DG, McShane LM, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med. 2012;9(5):e1001216.
   PubMed Web of Science ®Google Scholar
• McGuire JN, Overgaard J, Pociot F. Mass spectrometry is only one piece of the puzzle in clinical proteomics. Brief Funct Genomic Proteomic. 2008;7(1):74–83.
   PubMedGoogle Scholar
• Dakna M, Harris K, Kalousis A, et al Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics. 2010;11:594.
   PubMed Web of Science ®Google Scholar
• Drabovich AP, Saraon P, Jarvi K, et al. Seminal plasma as a diagnostic fluid for male reproductive system disorders. Nat Rev Urol. 2014;11(5):278–288.
   PubMed Web of Science ®Google Scholar
• Neuhaus J, Schiffer E, von Wilcke P, et al. Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease. PLoS One. 2013;8(6):e67514.
   PubMed Web of Science ®Google Scholar
• Hamelin-Peyron C, Vlaeminck-Guillem V, Haidous H, et al. Prostate cancer biomarker annexin A3 detected in urines obtained following digital rectal examination presents antigenic variability. Clin Biochem. 2014;47(10–11):901–908.
   PubMed Web of Science ®Google Scholar
• Vermassen T, Van Praet C, Lumen N, et al. Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancer. Prostate. 2015;75(3):314–322.
   PubMed Web of Science ®Google Scholar
• Vermassen T, VanPraet C, Vanderschaeghe D, et al. Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer. Electrophoresis. 2014;35(7):1017–1024.
   PubMed Web of Science ®Google Scholar